Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia

Blog Article

Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) constitutes a heterogeneous subset of ALL with a uniformly unfavorable prognosis.The identification of mutations amenable to treatment with tyrosine kinase-inhibitors (TKIs) represents a promising field of investigation.We report the case of a young patient affected by relapsed/refractory Ph-like ALL treated with chimeric antigen Sophorolipids Production from Oil Cake by Solid-State Fermentation. Inventory for Economic and Environmental Assessment receptor T (CAR-T) cells after successful bridging with compassionate-use ponatinib and low-dose prednisone.We restarted low-dose ponatinib maintenance three months later.

Twenty months later, measurable residual disease negativity and B-cell aplasia persist.To the best of our knowledge, this is the first Does Context Matter? Effective Deep Learning Approaches to Curb Fake News Dissemination on Social Media case reporting the use of ponatinib in Ph-like ALL as a bridge to and maintenance after CAR-T cell therapy.